A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs

PHASE3CompletedINTERVENTIONAL
Enrollment

509

Participants

Timeline

Start Date

August 8, 2014

Primary Completion Date

January 23, 2017

Study Completion Date

November 22, 2017

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Peficitinib

oral

DRUG

Placebo

oral

BIOLOGICAL

Etanercept

subcutaneous injection

Trial Locations (153)

Unknown

JP00037, Nagoya

JP00109, Nagoya

JP00130, Nagoya

JP00066, Okazaki

JP00140, Toyoake

JP00108, Toyohashi

JP00156, Toyota

JP00068, Yatomi

JP00102, Kamagaya

JP00127, Matsudo

JP00115, Narashino

JP00138, Yotsukaidō

JP00120, Iizuka

JP00040, Kitakyushu

JP00119, Kitakyushu

JP00071, Kurume

JP00097, Kurume

JP00106, Kurume

JP00033, Takasaki

JP00026, Asahikawa

JP00090, Hakodate

JP00125, Kushiro

JP00001, Sapporo

JP00002, Sapporo

JP00003, Sapporo

JP00031, Sapporo

JP00038, Sapporo

JP00114, Sapporo

JP00158, Sapporo

JP00056, Akashi

JP00069, Himeji

JP00113, Kakogawa

JP00041, Katō

JP00042, Kobe

JP00092, Kobe

JP00154, Kobe

JP00117, Nishinomiya

JP00107, Hitachi

JP00073, Koga

JP00054, Mito

JP00049, Morioka

JP00084, Isehara

JP00048, Kawasaki

JP00058, Kawasaki

JP00141, Sagamihara

JP00096, Yokohama

JP00128, Yokosuka

JP00057, Tamana

JP00004, Sendai

JP00027, Sendai

JP00036, Sendai

JP00105, Sendai

JP00151, Sendai

JP00050, Hyūga

JP00162, Isehaya

JP00101, Ōmura

JP00103, Ōmura

JP00153, Sasebo

JP00094, Kashihara

JP00025, Nagaoka

JP00144, Shibata

JP00064, Beppu

JP00051, Setouchi

JP00011, Hannan

JP00134, Higashiosaka

JP00078, Kawachi-Nagano

JP00137, Sakai

JP00070, Suita

JP00086, Suita

JP00061, Toyonaka

JP00075, Ureshino

JP00126, Gyōda

JP00007, Hiki

JP00082, Iruma

JP00060, Kawagoe

JP00161, Kawagoe

JP00062, Kawaguchi

JP00052, Sayama

JP00008, Tokorozawa

JP00133, Kakegawa

JP00077, Kanuma

JP00024, Bunkyo

JP00043, Bunkyo

JP00149, Bunkyo

JP00152, Bunkyo

JP00095, Chiyoda City

JP00099, Chiyoda City

JP00142, Chūō

JP00063, Hachiōji

JP00053, Kiyose

JP00072, Meguro City

JP00083, Meguro City

JP00148, Ōta-ku

JP00100, Setagaya City

JP00032, Shinjuku

JP00010, Takaoka

JP00155, Nishimuro

JP00104, Shimonoseki

JP00047, Shūnan

JP00018, Fukuoka

JP00020, Fukuoka

JP00035, Fukuoka

JP00059, Fukuoka

JP00067, Fukuoka

JP00076, Fukuoka

JP00131, Fukuoka

JP00164, Fukuoka

JP00013, Hiroshima

JP00014, Hiroshima

JP00015, Hiroshima

JP00016, Hiroshima

JP00055, Hiroshima

JP00065, Kagoshima

JP00074, Kagoshima

JP00093, Kochi

JP00022, Kumamoto

JP00046, Kumamoto

JP00123, Kyoto

JP00159, Kyoto

JP00023, Miyagi

JP00122, Miyazaki

JP00080, Nagano

JP00098, Nagasaki

JP00112, Nagasaki

JP00147, Nagasaki

JP00118, Okayama

JP00150, Osaka

JP00157, Osaka

JP00017, Ōita

JP00089, Shizuoka

JP00135, Shizuoka

JP00139, Toyama

KR00504, Daegu

KR00510, Daegu

KR00505, Gwangju

KR00506, Incheon

KR00508, Jeonju

KR00501, Seoul

KR00502, Seoul

KR00503, Seoul

KR00509, Seoul

KR00511, Seoul

KR00507, Suwon

TW00708, Kaohsiung City

TW00709, Kaohsiung City

TW00704, Taichung

TW00705, Taichung

TW00710, Taichung

TW00712, Tainan City

TW00701, Taipei

TW00702, Taipei

TW00711, Taipei

TW00703, Taoyuan District

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT02308163 - A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs | Biotech Hunter | Biotech Hunter